101 related articles for article (PubMed ID: 21484790)
1. In vivo pH in metabolic-defective Ras-transformed fibroblast tumors: key role of the monocarboxylate transporter, MCT4, for inducing an alkaline intracellular pH.
Chiche J; Le Fur Y; Vilmen C; Frassineti F; Daniel L; Halestrap AP; Cozzone PJ; Pouysségur J; Lutz NW
Int J Cancer; 2012 Apr; 130(7):1511-20. PubMed ID: 21484790
[TBL] [Abstract][Full Text] [Related]
2. Monocarboxylate transporter 4 deficiency enhances high-intensity interval training-induced metabolic adaptations in skeletal muscle.
Tamura Y; Jee E; Kouzaki K; Kotani T; Nakazato K
J Physiol; 2024 Apr; 602(7):1313-1340. PubMed ID: 38513062
[TBL] [Abstract][Full Text] [Related]
3. MCT4 knockdown by tumor microenvironment-responsive nanoparticles remodels the cytokine profile and eradicates aggressive breast cancer cells.
Abdellatif AAH; Bouazzaoui A; Tawfeek HM; Younis MA
Colloids Surf B Biointerfaces; 2024 Jun; 238():113930. PubMed ID: 38692174
[TBL] [Abstract][Full Text] [Related]
4. Monocarboxylate transporter 4 inhibition potentiates hepatocellular carcinoma immunotherapy through enhancing T cell infiltration and immune attack.
Fang Y; Liu W; Tang Z; Ji X; Zhou Y; Song S; Tian M; Tao C; Huang R; Zhu G; Jiang X; Gao J; Qu W; Wang H; Zhou P; Wu X; Jin L; Sun H; Ding Z; Peng Y; Zhao S; Zhou J; Fan J; Xu W; Shi Y
Hepatology; 2023 Jan; 77(1):109-123. PubMed ID: 35043976
[TBL] [Abstract][Full Text] [Related]
5. Macrophage MCT4 inhibition activates reparative genes and protects from atherosclerosis by histone H3 lysine 18 lactylation.
Zhang Y; Jiang H; Dong M; Min J; He X; Tan Y; Liu F; Chen M; Chen X; Yin Q; Zheng L; Shao Y; Li X; Chen H
Cell Rep; 2024 May; 43(5):114180. PubMed ID: 38733581
[TBL] [Abstract][Full Text] [Related]
6. Cancer: fundamentals behind pH targeting and the double-edged approach.
Koltai T
Onco Targets Ther; 2016; 9():6343-6360. PubMed ID: 27799782
[TBL] [Abstract][Full Text] [Related]
7. Glycolysis, tumor metabolism, cancer growth and dissemination. A new pH-based etiopathogenic perspective and therapeutic approach to an old cancer question.
Alfarouk KO; Verduzco D; Rauch C; Muddathir AK; Adil HH; Elhassan GO; Ibrahim ME; David Polo Orozco J; Cardone RA; Reshkin SJ; Harguindey S
Oncoscience; 2014; 1(12):777-802. PubMed ID: 25621294
[TBL] [Abstract][Full Text] [Related]
8. Genetic disruption of lactate/H+ symporters (MCTs) and their subunit CD147/BASIGIN sensitizes glycolytic tumor cells to phenformin.
Marchiq I; Le Floch R; Roux D; Simon MP; Pouyssegur J
Cancer Res; 2015 Jan; 75(1):171-80. PubMed ID: 25403912
[TBL] [Abstract][Full Text] [Related]
9. CD147 subunit of lactate/H+ symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of glycolytic tumors.
Le Floch R; Chiche J; Marchiq I; Naiken T; Ilc K; Murray CM; Critchlow SE; Roux D; Simon MP; Pouysségur J
Proc Natl Acad Sci U S A; 2011 Oct; 108(40):16663-8. PubMed ID: 21930917
[TBL] [Abstract][Full Text] [Related]
10. Dual Inhibition of the Lactate Transporters MCT1 and MCT4 Is Synthetic Lethal with Metformin due to NAD+ Depletion in Cancer Cells.
Benjamin D; Robay D; Hindupur SK; Pohlmann J; Colombi M; El-Shemerly MY; Maira SM; Moroni C; Lane HA; Hall MN
Cell Rep; 2018 Dec; 25(11):3047-3058.e4. PubMed ID: 30540938
[TBL] [Abstract][Full Text] [Related]
11. Metabolic support of tumour-infiltrating regulatory T cells by lactic acid.
Watson MJ; Vignali PDA; Mullett SJ; Overacre-Delgoffe AE; Peralta RM; Grebinoski S; Menk AV; Rittenhouse NL; DePeaux K; Whetstone RD; Vignali DAA; Hand TW; Poholek AC; Morrison BM; Rothstein JD; Wendell SG; Delgoffe GM
Nature; 2021 Mar; 591(7851):645-651. PubMed ID: 33589820
[TBL] [Abstract][Full Text] [Related]
12. Monocarboxylic acid transport.
Halestrap AP
Compr Physiol; 2013 Oct; 3(4):1611-43. PubMed ID: 24265240
[TBL] [Abstract][Full Text] [Related]
13. Synergistic suppressive effects on triple-negative breast cancer by the combination of JTC-801 and sodium oxamate.
Wang CY; Xuan DTM; Ye PH; Li CY; Anuraga G; Ta HDK; Lai MD; Hsu HP
Am J Cancer Res; 2023; 13(10):4661-4677. PubMed ID: 37970352
[TBL] [Abstract][Full Text] [Related]
14. How protons pave the way to aggressive cancers.
Swietach P; Boedtkjer E; Pedersen SF
Nat Rev Cancer; 2023 Dec; 23(12):825-841. PubMed ID: 37884609
[TBL] [Abstract][Full Text] [Related]
15. Lactate Efflux Inhibition by Syrosingopine/LOD Co-Loaded Nanozyme for Synergetic Self-Replenishing Catalytic Cancer Therapy and Immune Microenvironment Remodeling.
Wu S; Xu L; He C; Wang P; Qin J; Guo F; Wang Y
Adv Sci (Weinh); 2023 Sep; 10(26):e2300686. PubMed ID: 37386815
[TBL] [Abstract][Full Text] [Related]
16. Roles of non-coding RNAs in the metabolism and pathogenesis of bladder cancer.
Sanya DRA; Onésime D
Hum Cell; 2023 Jul; 36(4):1343-1372. PubMed ID: 37209205
[TBL] [Abstract][Full Text] [Related]
17. Lactate-related metabolic reprogramming and immune regulation in colorectal cancer.
Sun Q; Wu J; Zhu G; Li T; Zhu X; Ni B; Xu B; Ma X; Li J
Front Endocrinol (Lausanne); 2022; 13():1089918. PubMed ID: 36778600
[TBL] [Abstract][Full Text] [Related]
18. The Prime and Integral Cause of Cancer in the Post-Warburg Era.
Harguindey S; Reshkin SJ; Alfarouk KO
Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672490
[No Abstract] [Full Text] [Related]
19. High expression of monocarboxylate transporter 4 (MCT 4), but not MCT 1, predicts poor prognosis in patients with non-small cell lung cancer.
Tong YH; Hu XP; Xiang XP; Fang L
Transl Cancer Res; 2021 Mar; 10(3):1336-1345. PubMed ID: 35116459
[TBL] [Abstract][Full Text] [Related]
20. Integrative Analysis Identified MCT4 as an Independent Prognostic Factor for Bladder Cancer.
Zhao Y; Zhao B; Yan WH; Xia Y; Wang ZH; Zheng GY; Wang WD; Zhang YS
Front Oncol; 2021; 11():704857. PubMed ID: 34513685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
